DE69733834D1 - Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren - Google Patents
Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumorenInfo
- Publication number
- DE69733834D1 DE69733834D1 DE69733834T DE69733834T DE69733834D1 DE 69733834 D1 DE69733834 D1 DE 69733834D1 DE 69733834 T DE69733834 T DE 69733834T DE 69733834 T DE69733834 T DE 69733834T DE 69733834 D1 DE69733834 D1 DE 69733834D1
- Authority
- DE
- Germany
- Prior art keywords
- thyroxine
- hormonal activity
- treatment
- significant hormonal
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US833272 | 1992-02-10 | ||
US08/655,267 US5736576A (en) | 1996-06-04 | 1996-06-04 | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
US655267 | 1996-06-04 | ||
US08/833,272 US6017958A (en) | 1996-06-04 | 1997-04-03 | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
PCT/US1997/009086 WO1997046228A1 (en) | 1996-06-04 | 1997-05-30 | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69733834D1 true DE69733834D1 (de) | 2005-09-01 |
DE69733834T2 DE69733834T2 (de) | 2006-06-01 |
Family
ID=27096941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69733834T Expired - Lifetime DE69733834T2 (de) | 1996-06-04 | 1997-05-30 | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren |
Country Status (15)
Country | Link |
---|---|
US (1) | US6017958A (de) |
EP (1) | EP0954299B1 (de) |
JP (1) | JP4188416B2 (de) |
CN (1) | CN1154486C (de) |
AT (1) | ATE300292T1 (de) |
AU (1) | AU730261B2 (de) |
BR (1) | BR9710686A (de) |
CA (1) | CA2257235C (de) |
DE (1) | DE69733834T2 (de) |
DK (1) | DK0954299T3 (de) |
ES (1) | ES2246514T3 (de) |
IL (1) | IL127384A0 (de) |
NZ (1) | NZ333356A (de) |
PT (1) | PT954299E (de) |
WO (1) | WO1997046228A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922775A (en) * | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
KR20010042168A (ko) * | 1998-03-25 | 2001-05-25 | 바이오소스 테크놀로지스 인코포레이티드 | 혈관형성을 저해하는 벤조에이트 유도체 |
US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
AU1624801A (en) | 1999-11-19 | 2001-05-30 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
US20050159490A1 (en) * | 2001-01-31 | 2005-07-21 | Eugene Morkin | Method to treat chronic heart failure and/or elevated cholesterol levels |
US7504435B2 (en) | 2001-01-31 | 2009-03-17 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for stimulating weight loss and/or for lowering triglycerides in patients |
AUPR500201A0 (en) | 2001-05-14 | 2001-06-07 | Commonwealth Scientific And Industrial Research Organisation | Recovery of minerals by flotation |
CA2487388C (en) | 2002-06-06 | 2011-05-10 | Canbas Co., Ltd. | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
JP2007501608A (ja) * | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | 抗癌治療の効力を推定するための感受性試験 |
US20050249667A1 (en) * | 2004-03-24 | 2005-11-10 | Tuszynski Jack A | Process for treating a biological organism |
NZ587586A (en) * | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
JP5324785B2 (ja) | 2005-10-28 | 2013-10-23 | 武田薬品工業株式会社 | 複素環アミド化合物及びその用途 |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
EP2038654A4 (de) * | 2006-06-12 | 2010-08-11 | Bipar Sciences Inc | Verfahren zur behandlung von krankheiten mit parp-hemmern |
WO2008030891A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
EP2059802A4 (de) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | Verfahren für den entwurf von parp-hemmern und ihre verwendung |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
CN101522609A (zh) * | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
WO2008039941A2 (en) * | 2006-09-27 | 2008-04-03 | The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services | Scgb3a2 as a growth factor and anti-apoptotic agent |
JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ,インコーポレイティド | ベンゾピロン系parp阻害剤を用いる癌の処置方法および組成物 |
CN101918003A (zh) * | 2007-11-12 | 2010-12-15 | 彼帕科学公司 | 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌 |
CN101917982B (zh) * | 2007-11-12 | 2013-03-20 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌 |
AU2008333786A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
WO2011135574A1 (en) | 2010-04-28 | 2011-11-03 | Osnat Ashur-Fabian | Methods, compositions and kits for providing a therapeutic treatment |
US20150231101A1 (en) * | 2012-08-20 | 2015-08-20 | Merck Patent Gmbh | Solid pharmaceutical preparation containing levothyroxine |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
KR20190107656A (ko) | 2016-11-02 | 2019-09-20 | 이뮤노젠 아이엔씨 | 항체-약물 콘주게이트 및 parp 억제제로 병용 치료 |
WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | METHODS OF TREATING GLIOBLASTOMA |
WO2019067991A1 (en) | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND USES THEREOF |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB643089A (en) * | 1947-10-23 | 1950-09-15 | Glaxo Lab Ltd | Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers |
GB642159A (en) * | 1947-10-23 | 1950-08-30 | Glaxo Lab Ltd | Improvements in or relating to the preparation of diphenyl ethers |
US4724234A (en) * | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
US4816255A (en) * | 1985-07-31 | 1989-03-28 | Ghent William R | Treatment of iodine deficiency breast syndrome |
WO1993002444A1 (en) * | 1991-07-24 | 1993-02-04 | Vladislav Vladimirovich Volkov | Tensioning device for keyboard stringed musical instrument |
AU4090093A (en) * | 1992-05-29 | 1993-12-30 | Yamanouchi Pharmaceutical Co., Ltd. | Medicine containing benzoic acid derivative and novel benzoic acid derivative |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
US5883294A (en) * | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
US5922775A (en) * | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
-
1997
- 1997-04-03 US US08/833,272 patent/US6017958A/en not_active Expired - Lifetime
- 1997-05-30 PT PT97927813T patent/PT954299E/pt unknown
- 1997-05-30 AT AT97927813T patent/ATE300292T1/de active
- 1997-05-30 NZ NZ333356A patent/NZ333356A/en not_active IP Right Cessation
- 1997-05-30 CA CA002257235A patent/CA2257235C/en not_active Expired - Fee Related
- 1997-05-30 IL IL12738497A patent/IL127384A0/xx unknown
- 1997-05-30 WO PCT/US1997/009086 patent/WO1997046228A1/en active IP Right Grant
- 1997-05-30 BR BR9710686-0A patent/BR9710686A/pt not_active Application Discontinuation
- 1997-05-30 AU AU32182/97A patent/AU730261B2/en not_active Ceased
- 1997-05-30 CN CNB971969795A patent/CN1154486C/zh not_active Expired - Fee Related
- 1997-05-30 DE DE69733834T patent/DE69733834T2/de not_active Expired - Lifetime
- 1997-05-30 DK DK97927813T patent/DK0954299T3/da active
- 1997-05-30 ES ES97927813T patent/ES2246514T3/es not_active Expired - Lifetime
- 1997-05-30 JP JP50067098A patent/JP4188416B2/ja not_active Expired - Lifetime
- 1997-05-30 EP EP97927813A patent/EP0954299B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1154486C (zh) | 2004-06-23 |
DE69733834T2 (de) | 2006-06-01 |
CN1226826A (zh) | 1999-08-25 |
EP0954299B1 (de) | 2005-07-27 |
ES2246514T3 (es) | 2006-02-16 |
US6017958A (en) | 2000-01-25 |
AU730261B2 (en) | 2001-03-01 |
CA2257235A1 (en) | 1997-12-11 |
ATE300292T1 (de) | 2005-08-15 |
NZ333356A (en) | 2000-06-23 |
JP4188416B2 (ja) | 2008-11-26 |
JP2001501590A (ja) | 2001-02-06 |
DK0954299T3 (da) | 2005-10-31 |
AU3218297A (en) | 1998-01-05 |
BR9710686A (pt) | 2000-01-11 |
IL127384A0 (en) | 1999-10-28 |
CA2257235C (en) | 2007-01-30 |
EP0954299A1 (de) | 1999-11-10 |
PT954299E (pt) | 2005-11-30 |
EP0954299A4 (de) | 2000-09-06 |
WO1997046228A1 (en) | 1997-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69733834D1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
ATE222489T1 (de) | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren | |
DE69634900D1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
DE69737066D1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
DE69839586D1 (de) | Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung | |
DE69127175D1 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
EA200400632A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
ATE282425T1 (de) | Verfahren zur behandlung von endothelialen verletzungen | |
DE3789082D1 (de) | Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors. | |
ATE249233T1 (de) | Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen | |
ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
DE60039730D1 (de) | Genetisch manipulierte Herpesviren zur Behandlung von Tumoren | |
NO994330L (no) | Metode for behandling av en tumor | |
NO932101D0 (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: OCTAMER, INC., TIBURON, CARLIF., US |
|
8364 | No opposition during term of opposition |